Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.100 Biomarker disease BEFREE EMSY is located within an amplicon in sporadic breast and ovarian cancers, suggesting that its overexpression may mimic the effects of BRCA2 inactivation. 14651841 2003
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.100 GeneticVariation disease BEFREE The remarkable clinical overlap between sporadic EMSY amplification and familial BRCA2 deletion implicates a BRCA2 pathway in sporadic breast and ovarian cancer. 14651845 2003
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.080 GeneticVariation disease BEFREE The remarkable clinical overlap between sporadic EMSY amplification and familial BRCA2 deletion implicates a BRCA2 pathway in sporadic breast and ovarian cancer. 14651845 2003
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.070 GeneticVariation disease BEFREE The remarkable clinical overlap between sporadic EMSY amplification and familial BRCA2 deletion implicates a BRCA2 pathway in sporadic breast and ovarian cancer. 14651845 2003
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.070 GeneticVariation disease LHGDN The remarkable clinical overlap between sporadic EMSY amplification and familial BRCA2 deletion implicates a BRCA2 pathway in sporadic breast and ovarian cancer. 14651845 2003
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.040 Biomarker phenotype BEFREE The BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis. 14651841 2003
CUI: C3160889
Disease: Node-negative breast cancer
Node-negative breast cancer 		0.010 Biomarker disease BEFREE In addition, EMSY amplification is associated with worse survival, particularly in node-negative breast cancer, suggesting that it may be of prognostic value. 14651845 2003
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.380 Biomarker disease BEFREE EMSY links breast cancer gene 2 to the 'Royal Family'. 15318925 2004
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.370 Biomarker disease BEFREE EMSY links breast cancer gene 2 to the 'Royal Family'. 15318925 2004
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.050 AlteredExpression group BEFREE EMSY RNA expression levels were studied along with those of five other genes located at 11q13.5 by real-time quantitative PCR in the 39 cell lines and a subset of 65 tumors. 15355907 2004
CUI: C1336076
Disease: Sporadic Breast Carcinoma
Sporadic Breast Carcinoma 		0.040 Biomarker disease BEFREE Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. 15355907 2004
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.380 AlteredExpression disease BEFREE These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer. 16145051 2005
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.370 AlteredExpression disease BEFREE These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer. 16145051 2005
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.320 AlteredExpression group LHGDN Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. 16145051 2005
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.100 GeneticVariation disease BEFREE We found no association between common genetic variation in EMSY and risk of breast or ovarian cancer in two large study sets of white British women. 16029503 2005
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.080 GeneticVariation disease BEFREE We found no association between common genetic variation in EMSY and risk of breast or ovarian cancer in two large study sets of white British women. 16029503 2005
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.070 GeneticVariation disease BEFREE We found no association between common genetic variation in EMSY and risk of breast or ovarian cancer in two large study sets of white British women. 16029503 2005
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.070 GeneticVariation disease LHGDN We used a genetic association study design to determine if common genetic variation (frequency > or = 5%) in EMSY was associated with breast or ovarian cancer risk in the British population. 16029503 2005
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.100 Biomarker disease BEFREE EMSY amplification was assessed by fluorescent in-situ hybridization (FISH) in 674 ovarian cancers in a tissue microarray and correlated with histopathological subtype and tumor grade. 16236351 2006
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.080 Biomarker disease BEFREE These findings support the role of EMSY as a key oncogene within the 11q13 amplicon in ovarian cancer. 16236351 2006
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.070 Biomarker disease LHGDN EMSY amplification was seen in 52/285 (18%) high grade papillary serous carcinomas, 4/27 (15%) high grade endometrioid carcinomas, 3/38 (8%) clear cell carcinomas, and 3/10 (30%) undifferentiated carcinomas. aCGH mapping of 11q13 in ovarian cancer showed that EMSY localized to the region with the highest frequency of copy number gain. 16236351 2006
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.070 Biomarker disease BEFREE These findings support the role of EMSY as a key oncogene within the 11q13 amplicon in ovarian cancer. 16236351 2006
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.010 Biomarker group BEFREE EMSY amplification was seen in 52/285 (18%) high grade papillary serous carcinomas, 4/27 (15%) high grade endometrioid carcinomas, 3/38 (8%) clear cell carcinomas, and 3/10 (30%) undifferentiated carcinomas. aCGH mapping of 11q13 in ovarian cancer showed that EMSY localized to the region with the highest frequency of copy number gain. 16236351 2006
CUI: C0205698
Disease: Undifferentiated carcinoma
Undifferentiated carcinoma 		0.010 Biomarker disease BEFREE EMSY amplification was seen in 52/285 (18%) high grade papillary serous carcinomas, 4/27 (15%) high grade endometrioid carcinomas, 3/38 (8%) clear cell carcinomas, and 3/10 (30%) undifferentiated carcinomas. aCGH mapping of 11q13 in ovarian cancer showed that EMSY localized to the region with the highest frequency of copy number gain. 16236351 2006
CUI: C0206687
Disease: Carcinoma, Endometrioid
Carcinoma, Endometrioid 		0.010 Biomarker disease BEFREE EMSY amplification was seen in 52/285 (18%) high grade papillary serous carcinomas, 4/27 (15%) high grade endometrioid carcinomas, 3/38 (8%) clear cell carcinomas, and 3/10 (30%) undifferentiated carcinomas. aCGH mapping of 11q13 in ovarian cancer showed that EMSY localized to the region with the highest frequency of copy number gain. 16236351 2006